Today in Focus: KOD

Trading Services I Use in my Trading:

StockAnalysis.com - I’ve been using Stock Analysis as an affordable but reliable method of looking at New and Upcoming IPOs, Earnings Calendars and most notably KPIs (Key Performance Indicators). Stock Analysis allows you to view the KPIs for many companies with up to date metrics and segments that you can cross reference against Earnings Results. This is incredibly important when understanding what metrics move a stock. At $65 per year it’s a no brainer. They’ve given me a discount code if you use IRISHBORNINVESTOR they will give you another 10% Off.

Market Condition: Market Under all MAs, VIX Strong

Commentary: Red open again. Nothing has changed. Trump is ratcheting up the language again this morning. Into the weekend.

Caution advised. Today’s pick is a Biotech which are generally disconnected from the market. Not much more needs to be said. A flush is still in play in the coming days I am much more selective in the last week.

Current Positions: SEI, FSLY, NBIS, YOU, NKTR, AMPX, MRVL, DELL, SWBI, NIO, FIVE, ARM

In Play

KOD:  Positive Phase 3 Data

Key Metrics KOD: Industry Group: Biotechnology, Market Cap: 2.07B, Float: 56.69M, Short Interest: 12.43%, Days to Cover: 9.69, Sales Y/Y TTM: -, EPS Y/Y TTM: -12.93%, Earnings: Nov 13 AMC, Exchange: NASDAQ

Catalyst: Announced positive topline results from GLOW2, the confirmatory Phase 3 study of Zenkuda (tarcocimab tedromer) in diabetic retinopathy (DR). Gold Standard trial design. Excellent safety. 62.5% of Zenkuda patients achieved ≥2-step DRSS improvement vs. 3.3% sham (p<0.0001). Management is accelerating BLA submission timeline

Chart is good but not overly neglected. This is an institutional favored name. Baker Bros (Top Tier in Biotech Funds) have been increasing their stake and recent Insider buying. High short interest. Seems to be overcooking somewhat in the pre market but this is an A+ Catalyst.

In terms of financing they are highly likely to dilute by way of private placement as they have 2 Quarters of cash remaining.

"Zenkuda has the potential to shift the equation for physicians and patients by offering durable disease control." — Dr. Charles Wykoff

"We now have a multi-indication BLA-ready profile for Zenkuda, and we intend to accelerate our BLA submission plans." — Dr. Victor Perlroth, CEO

Delayed Reaction Watchlist (TradingView Link)

_{Note: This is my methodology for identifying stocks in play. There are many valid approaches to trading catalysts—find the setups, timeframes, and risk parameters that align with your strategy.}